A 45-year-old woman presented with a metastatic breast carcinoma and was treated with capecitabine, oral vinorelbine and trastuzumab combination therapy. The initial echocardiogram and the ECG were considered normal. She began treatment with 3-weekly cycles of the combination therapy. After the fourth dose of capecitabine, she presented with severe chest and arm pain, which was responsive to nitroglycerine spray. ECG at admission demonstrated tachycardia with ST-segment elevation suggesting ischemia. The clinical symptoms returned to baseline after a few hours and within 24 h the ECG showed inverted T in leads V3–V6. Cardiac ultrasonography revealed hypokinesia in the left ventricle without segmentary hypokinesia, with mildly reduced global systolic function, which normalized 1 week later. Two weeks later, she was rechallenged with capecitabine. After the fourth dose, the patient developed chest pain. ECG showed infero-apico-lateral injury, which normalized after administration of nitrates, nicorandil and verapamil and discontinuation of capecitabine. This case suggests that capecitabine can lead to the cardiotoxicity characteristic of other fluoropyrimidines. Therefore, it is important to inform patients about the risk of angina-like chest pain, to stop treatment immediately if symptoms occur, and to monitor the patient in hospital. Fluoropyrimidine rechallenge should be avoided because of the risk of ischemic event or sudden death.

Keywords:
Cardiac toxicity, Capecitabine, Fluoropyrimidine
1.
Miwa M, Ura M, Nishida M, et al: Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998;34:1274–1281.
2.
Schuller J, Cassidy J, Dumont E, et al: Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 2000;45:291–297.
3.
Dent RG, McColl I: 5-fluorouracil and angina. Lancet 1975;1:347–348.
4.
Tsavaris N, Kosmas C, Vadiaka M, et al: Cardiotoxicity following different doses and schedules of 5-fluorouracil administration for malignancy: a survey of 427 patients. Med Sci Monit 2002;8:P151–P157.
5.
Labianca R, Beretta G, Clerici M, et al: Symptomatic cardiotoxicity associated with 5-fluorouracil: a study on 1,083 patients. Tumori 1982;68:505–510.
6.
Tsibiribi P, Descotes J, Lombard-Bohas C, et al: Cardiotoxicity of 5-fluorouracil in 1,350 patients with no prior history of heart disease. Bull Cancer 2006;93:E27–E30.
7.
Freeman NJ, Constanza ME: 5-fluorouracil associated cardiotoxicity. Cancer 1988;61:36–45.
8.
Meyer CC, Calis KA, Burke LB, et al: Symptomatic cardiotoxicity associated with 5- fluorouracil. Pharmacotherapy 1997;17:729–736.
9.
de Forni M, Malet-Martino MC, Jaillais P, et al: Cardiotoxicity of high dose continuous infusion fluorouracil: a prospective clinical study. J Clin Oncol 1992;10:1795–1801.
10.
Abele R, Alberto P, Kaplan S, et al: Phase II study of doxifluridine in advanced colorectal adenocarcinoma. J Clin Oncol 1983;1:750–754.
11.
Kikuchi K, Majima S, Murakami M: Clinical survey on cardiotoxicity of tegafur (FT-207): compilation of a nationwide survey (in Japanese). Gan To Kagaku Ryoho 1982;9:1482–1488.
12.
Schnetzler B, Popova N, Collao Lamb C, et al: Coronary spasm induced by capecitabine. Ann Oncol 2001;12:723–724.
13.
Aksoy S, Karaca B, Dincer M, et al: Common etiology of capecitabine and fluorouracil-induced coronary vasospasm in a colon cancer patient. Ann Pharmacother 2005;39:573–574.
14.
Singer M: Cardiotoxicity and capecitabine: a case report. Clin J Oncol Nurs 2003;7:72–75.
15.
Bertolini A, Flumano M, Fusco O, et al: Acute cardiotoxicity during capecitabine treatment: a case report. Tumori 2001;87:200–206.
16.
Frickhofen N, Beck FJ, Jung B, et al: Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil. Ann Oncol 2002;13:797–801.
17.
Camps C, Godes M, Soler JJ: Possible cardiotoxicity induced by orally administered fluoropyrimidines. An Med Interna 1990;7:525–527.
18.
Rosati G, Cordio S, Tucci A, et al: A phase II trial of oxaliplatin (L-OHP) and uracil-tegafur (UFT)/folinic acid (FA) for advanced colorectal cancer (ACC) in elderly patents. ASCO Meet Abstr 2004:3681.
19.
Meydan N, Kundak I, Tugba Y, et al: Cardiotoxicity of de Gramont’s regimen: incidence, clinical characteristics and long-term follow-up. Jpn J Clin Oncol 2005;35:265–270.
20.
Smith KL, Dang C, Seidman AD: Cardiac dysfunction associated with trastuzumab. Expert Opin Drug Saf 2006;5:619–629.
21.
Hayes DF, Picard MH: Heart of darkness: the downside of trastuzumab. J Clin Oncol 2006;24:4056–4058.
22.
Akhtar S, Salim K, Bano Z: Symptomatic cardiotoxicity with high-dose 5-fluorouracil infusion: a prospective study. Oncology 1993;50:441–444.
23.
Rezkalla S, Kloner RA, Ensley J, et al: Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective clinical study. J Clin Oncol 1999;7:509–514.
24.
Stevenson DL, Mikhailidis DP, Gillett DS: Cardiotoxicity of 5-fluorouracil. Lancet 1977;2:406–407.
25.
Kuzel T, Esparaz B, Green D, Kies M: Thrombogenicity of intravenous 5-fluorouracil alone or in combination with cisplatin. Cancer 1990;65:885–889.
26.
Collins C, Weiden PL: Cardiotoxicity of 5-fluorouracil. Cancer Treat Rep 1987;71:733–736.
27.
Patel B, Kloner RA, Ensley J, et al: 5-fluorouracil cardiotoxicity: left ventricular dysfunction and effect of coronary vasodilators. Am J Med Sci 1987;294:238–243.
28.
Levillain R: Experimental myocarditis; anatomical study of 210 rat hearts after ingestion of 5-fluourouacil. CR Séances Soc Biol Fil 1972;166:340–342.
29.
Matsubara I, Kamiya J, Imai S: Cardiotoxic effects of 5-fluorouracil in the guinea pig. Jpn J Pharmacol 1980;30:871–879.
30.
Van Cutsem E, Hoff PM, Blum JL, et al: Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil. Ann Oncol 2002;13:484–485.
31.
Jensen SA, Sorensen JB: Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine. Cancer Chemother Pharmacol 2006;58:487–493.
32.
Kuppens IE, Boot H, Beijnen JH, et al: Capecitabine induces severe angina-like chest pain. Ann Intern Med 2004;140:494–495.
33.
Cianci G, Morelli MF, Cannita K, et al: Prophylactic options in patients with 5-fluorouracil-associated cardiotoxicity. Br J Cancer 2003;88:1507–1509.
34.
Capecitabine prescribing information, 2006.
35.
Takebayashi Y, Akiyama S, Akiba S, et al: Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma. J Natl Cancer Inst 1996;88:1110–1117.
36.
Takahashi Y, Bucana CD, Liu W, et al: Platelet-derived endothelial cell growth factor in human colon cancer angiogenesis: role of infiltrating cells. J Natl Cancer Inst 1996;88:1146–1151.
37.
Griffiths L, Dachs GU, Bicknell R, Harris AL, Stratford IJ: The influence of oxygen tension and pH on the expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast tumor cells grown in vitro and in vivo. Cancer Res 1997;57:570–572.
38.
Cwikiel M, Eskilsson J, Wieslander JB, Stjernquist U, Albertsson M: The appearance of endothelium in small arteries after treatment with 5-fluorouracil. An electron microscopic study of late effects in rabbits. Scanning Microsc 1996;10:805–818; discussion 819.
39.
Mancuso L: Prinzmetal’s angina during 5-fluorouracil chemotherapy. Am J Med 1987;83:602.
40.
Mosseri M, Fingert HJ, Varticovski L, et al: In vitro evidence that myocardial ischemia resulting from 5-fluorouracil chemotherapy is due to protein kinase C-mediated vasoconstriction of vascular smooth muscle. Cancer Res 1993;53:3028–3033.
41.
Sudhoff T, Enderle MD, Pahlke M, et al: 5-fluorouracil induces arterial vasocontraction. Ann Oncol 2004;15:661–664.
42.
Shoemaker LK, Arora U, Rocha Lima CM: 5-Fluorouracil induced coronary vasospasm. Cancer Control 2004;11:46–49.
43.
Rizvi AA, Schauer P, Owlia D, et al: Capecitabine-induced coronary vasospasm: a case report. Angiology 2004;55:93–97.
44.
Wardley A, et al: Trastuzumab plus docetaxel with or without capecitabine in patients with HER2-positive advanced/metastatic breast cancer: primary efficacy results from a randomised phase II study (CHAT). ESMO 31st Congress, Istanbul (LBA6), presented October 2, 2006.
45.
Xu L, Song S, Zhu J, et al: A phase II trial of trastuzumab (H) + capecitabine (X) as first-line treatment in patients (pts) with HER2-positive metastatic breast cancer (MBC). Ann Oncol 2006;17 (suppl 9):ix76 (abstract 169P).
46.
Lybaert W, Wildiers H, Neven P, et al: Multicentre phase II study of capecitabine (X), docetaxel (T) ± trastuzumab (H) as neoadjuvant treatment for patients (pts) with locally advanced breast cancer (LABC): preliminary safety and efficacy results. Ann Oncol 2006;17 (suppl 9):ix73 (abstract 154P).
47.
Ghosn M, Kattan J, Farhat F, Younes F, Gasmi J: Phase II trial of capecitabine and vinorelbine as first-line chemotherapy for metastatic breast cancer patients. Anticancer Res 2006;26:2451–2456.
48.
Lorusso V, Spada M, Giampaglia M, et al: Oral vinorelbine plus capecitabine (oral vincap) combination in patients with advanced breast cancer (ABC): a phase II study of the GOIM (Gruppo Oncologico dell’Italia Meridionale). Ann Oncol 2006;17(suppl 7):vii15–vii17.
49.
Nole F, Catania C, Sanna G, et al: Dose-finding and pharmacokinetic study of an all-oral combination regimen of oral vinorelbine and capecitabine for patients with metastatic breast cancer. Ann Oncol 2006;17:322–329.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.